Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations

Michele Carbone, Harvey I Pass, Guntulu Ak, H Richard Alexander, Paul Baas, Francine Baumann, Andrew M Blakely, Raphael Bueno, Aleksandra Bzura, Giuseppe Cardillo, Jane E Churpek, Irma Dianzani, Assunta De Rienzo, Mitsuru Emi, Salih Emri, Emanuela Felley-Bosco, Dean A Fennell, Raja M Flores, Federica Grosso, Nicholas K HaywardMary Hesdorffer, Chuong D Hoang, Peter A Johansson, Hedy L Kindler, Muaiad Kittaneh, Thomas Krausz, Aaron Mansfield, Muzaffer Metintas, Michael Minaai, Luciano Mutti, Maartje Nielsen, Kenneth O'Byrne, Isabelle Opitz, Sandra Pastorino, Francesca Pentimalli, Marc de Perrot, Antonia Pritchard, Robert Taylor Ripley, Bruce Robinson, Valerie Rusch, Emanuela Taioli, Yasutaka Takinishi, Mika Tanji, Anne S Tsao, A Murat Tuncer, Sebastian Walpole, Andrea Wolf, Haining Yang, Yoshie Yoshikawa, Alicia Zolodnick

Research output: Contribution to journalReview articlepeer-review

45 Citations (Scopus)


The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma; less frequently breast cancer, several types of skin carcinomas and other tumor types. Mesotheliomas in these patients are significantly less aggressive and patients require a multidisciplinary approach that involves genetic counseling, medical genetics, pathology, surgical, medical and radiation oncology expertise. Some BAP1 carriers have asymptomatic mesothelioma that can be followed by close clinical observation without apparent adverse outcomes: they may survive many years without therapy. Others may grow aggressively but very often respond to therapy. Detecting BAP1 germline mutations has, therefore, significant medical, social and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life and is also cost-effective. The co-authors of this paper are those who have published the vast majority of cases of mesothelioma occurring in patients carrying inactivating germline BAP1 mutations and who have studied the families affected by the BAP1 cancer syndrome for many years. This paper reports our experience. It is intended to be a source of information for all physicians who care for patients carrying germline BAP1 mutations. We discuss the clinical presentation, diagnostic and treatment challenges and our recommendations of how to best care for these patients and their family members, as well as the potential economic and psychosocial impact.

Original languageEnglish
JournalJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Early online date21 Apr 2022
Publication statusE-pub ahead of print - 21 Apr 2022


Dive into the research topics of 'Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations'. Together they form a unique fingerprint.

Cite this